ZTS

Zoetis Inc.

Healthcare
77.59 +1.20 +1.57% Market Closed
2026-06-03 • USD

Key Metrics

Market Cap 32.53B
EV —
Shares Out 419.23M
Revenue (ttm) 9.53B
Net Income 2.67B
Beta —
P/E 12.26
Forward P/E —
EPS (ttm) $6.10
P/S 3.44
P/B 10.13
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA 17.63%
ROE 65.09%
ROIC —
Gross Margin —
Oper. Margin —
Profit Margin 28.03%
Debt/Eq 2.86
LT Debt/Eq 73.67%
Quick Ratio —
Current Ratio 3.15
Book/sh 7.66
Cash/sh 4.6
Div Yield 2.53%
Div TTM $1.96
Payout Ratio 32.16%
SMA20 -3.25%
SMA50 -24.32%
SMA200 -37.86%
Volume 8,103,334
Avg Volume 5.45M
Rel Volume —
Perf Week -0.13%
Perf Month -31.06%
Perf Quarter -36.52%
Perf Half Y -34.61%
Perf YTD -38.33%
Perf Year -53.98%
Perf 3Y -54.66%
Perf 5Y -55.71%

Factor Lens

Seasonal Performance

Dividends

Per-share amounts adjusted for stock splits.

Last Dividend $0.5300
TTM Yield 2.53%
TTM Amount $1.96
Payout Ratio 32.16%
3-Yr Growth (CAGR) 14.57%
5-Yr Growth (CAGR) 19.02%

Last 12 Payouts

Period Ex-Date Amount / Share
Q1 2026 ~2026-03-31 $0.5300
Q2 2025 ~2025-06-30 $0.5000
Q1 2025 ~2025-03-31 $0.5000
Q2 2024 ~2024-06-30 $0.4320
Q1 2024 ~2024-03-31 $0.4320
Q2 2023 ~2023-06-30 $0.3750
Q1 2023 ~2023-03-31 $0.3750
Q2 2022 ~2022-06-30 $0.3250
Q1 2022 ~2022-03-31 $0.3250
Q2 2021 ~2021-06-30 $0.2500
Q1 2021 ~2021-03-31 $0.2500
Q2 2020 ~2020-06-30 $0.2000

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Zoetis Inc. is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The company has a diversified business with approximately 300 comprehensive product lines commercialized across eight core species: dogs, cats and horses (companion animals) and cattle, swine, poultry, fish and sheep (livestock); and within seven major product categories: parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceuticals and animal health diagnostics. Companion animal products represented approximately 70% of revenue for 2025, while livestock products represented approximately 29%, with the remaining 1% from Client Supply Services (contract manufacturing) and human health diagnostics. The company operates in two segments: United States (54% of revenue) and International (45% of revenue). With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, pet owners, and livestock producers worldwide. The company also provides solutions in biodevices, genetic testing and precision animal health.

Name
Zoetis Inc.
Industry
Drug Manufacturers - General
CEO
Kristin C. Peck · Chief Executive Officer
Employees
14,500 as of 2025-12-31
IPO Date
2020-01-14
Phone
(973) 822-7000
Address
10 Sylvan Way, Parsippany, NJ 07054
Website
www.zoetis.com

Key Executives

Name Title FY Pay
Roxanne Lagano Executive Vice President, General Counsel and Corporate Secretary —
Kristin C. Peck Chief Executive Officer —

Latest News